ArticleStem cell research & therapy2025
Mesenchymal stem/stromal cells overexpressing leukemia inhibitory factor (LIF) promote arteriogenesis and functional recovery in a mouse model of critical hindlimb ischemia.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCritical limb ischemia (CLI) is the most severe manifestation of peripheral arterial disease (PAD), for which there are still no effective therapeutic options. Mesenchymal stem/stromal cells (MSCs) can secrete bioactive molecules capable of promoting tissue regeneration and neovascularization. The therapeutic potential of MSCs can be enhanced by genetic modification to overexpress molecules of interest. Here, we produced an umbilical cord-derived MSC line overexpressing leukemia inhibitory factor (LIF), MSC_LIF, and evaluated its pro-angiogenic/arteriogenic potential.
methodsMSCs were transduced using a second-generation lentiviral system to express LIF. Transgene overexpression was confirmed by qRT-PCR and ELISA. The transcriptional and secretory profile of MSC_LIF was accessed by qRT-PCR and angiogenic protein array. The pro-angiogenic/arteriogenic potential of MSC_LIF was tested by counting microvessel sprouting in the in vitro 3D aortic ring model, in addition to measuring hemoglobin with Drabkin's reagent and quantifying CD31
resultsGene expression analysis demonstrated that MSC_LIF upregulates strategic genes in the neovascularization process and the secretion of angiogenic proteins. MSC_LIF increased the number of microvessel sprouting in aortic rings and promoted enhanced migration of endogenous vasculature into the Matrigel plugs. Intramuscular administration of MSC_LIF was able to restore blood flow in the ischemic paw due to the formation of CD31
conclusionLIF overexpression is a promising strategy to increase the potential of MSC in the treatment of CLI and for tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.